Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.60 USD
Change Today +0.12 / 1.27%
Volume 654.4K
MDXG On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

mimedx group inc (MDXG) Snapshot

Open
$9.42
Previous Close
$9.48
Day High
$9.60
Day Low
$9.35
52 Week High
07/17/15 - $13.20
52 Week Low
10/2/14 - $6.81
Market Cap
1.0B
Average Volume 10 Days
1.4M
EPS TTM
$0.15
Shares Outstanding
108.9M
EX-Date
--
P/E TM
64.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for MIMEDX GROUP INC (MDXG)

Related News

No related news articles were found.

mimedx group inc (MDXG) Related Businessweek News

No Related Businessweek News Found

mimedx group inc (MDXG) Details

MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix. The company’s AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas. Through its donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. The company processes the human amniotic membrane utilizing its proprietary PURION Process to produce a safe and effective implant. Its CollaFix technology platform is a collagen fiber technology, developed with its patented cross-linking polymers, designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues in order to augment their repair. MiMedx Group supplies approximately 400,000 allografts for application in the wound care, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare through direct sales force, independent sales representatives, and distributors, as well as through private label or OEM relationships. The company was incorporated in 2008 and is headquartered in Marietta, Georgia.

386 Employees
Last Reported Date: 03/13/15
Founded in 2008

mimedx group inc (MDXG) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $914.9K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $422.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $295.0K
Compensation as of Fiscal Year 2014.

mimedx group inc (MDXG) Key Developments

MiMedx Group, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter of 2015; Reaffirms Earnings Guidance for the Ear 2015

MiMedx Group, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company recorded record revenue for the second quarter of 2015 of $45.7 million, a $20.1 million or 79% increase over 2014 second quarter revenue of $25.6 million. Adjusted EBITDA was $10.6 million, a $7.7 million or 265% improvement, as compared to adjusted EBITDA of $2.9 million for the second quarter of 2014. Net income for the second quarter of 2015 was $5.4 million, or $0.05 per diluted common share, a $5.8 million improvement, as compared to the net loss of $390,000, or $0.00 per diluted common share, in the second quarter of 2014. Operating income was $5,652,000 compared to operating loss of $392,000 a year ago. Income before income tax provision was $5,653,000 compared to loss before income tax provision of $400,000 a year ago. Adjusted EBITDA was $10,562,000 compared to $2,894,000 a year ago. Net cash flows from operating activities were $2,932,000 compared to $1,179,000 a year ago. Purchases of equipment amounted to $1,166,000 compared to $679,000 a year ago. For the six months ended June 30, 2015, the company recorded record revenue of $86.4 million, a $41.3 million or 92% increase over revenue of $45.1 million recorded in the same period of 2014. Adjusted EBITDA for the six months ended June 30, 2015, was $19.3 million, a $14.4 million or 297% improvement, as compared to adjusted EBITDA of $4.9 million for the six months ended June 30, 2014. Net Income was $9.5 million, or $0.08 per diluted common share, a $10.8 million improvement, as compared to the Net Loss of $1.3 million, or $0.01 per diluted common share, in the first six months of 2014. Operating income was $9,899,000 compared to operating loss of $1,283,000 a year ago. Income before income tax provision was $9,886,000 compared to loss before income tax provision of $1,312,000 a year ago. Adjusted EBITDA was $19,326,000 compared to $4,870,000 a year ago. Net cash flows from operating activities were $7,143,000 compared to net cash flows used in operating activities of $432,000 a year ago. Purchases of equipment amounted to $2,513,000 compared to $1,145,000 a year ago. The company's guidance for the third quarter of 2015 includes: revenue in the range of $47 million to $50 million; and operating profit between 13% and 14%. The company's reiterated full year 2015 revenue guidance in the range of $180 million to $190 million. Due to the decision to accelerate certain growth related investments, the company is now projecting full year Operating margin in the range of 12% to 14%.

MiMedx Group, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 05:00 PM

MiMedx Group, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 05:00 PM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Michael J. Senken, Chief Financial Officer, Principal Accounting Officer and Vice President, Parker H. Petit, Chairman and Chief Executive Officer, William Charles Taylor, President, Chief Operating Officer and Director.

MiMedx Group, Inc. to Report Q2, 2015 Results on Jul 30, 2015

MiMedx Group, Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDXG:US $9.60 USD +0.12

MDXG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliqua BioMedical Inc $4.40 USD +0.11
Derma Sciences Inc $5.93 USD +0.02
Medtronic PLC $73.56 USD +0.04
Osiris Therapeutics Inc $18.73 USD +0.59
Smith & Nephew PLC 1,163 GBp +29.00
View Industry Companies
 

Industry Analysis

MDXG

Industry Average

Valuation MDXG Industry Range
Price/Earnings 65.3x
Price/Sales 6.3x
Price/Book 11.1x
Price/Cash Flow 57.4x
TEV/Sales 6.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MIMEDX GROUP INC, please visit www.mimedx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.